The amount of additional gross proceeds available upon exercise of warrants.

No definition available.

Name:	ibio_AdditionalGrossProceedsAvailableUponExerciseOfWarrants
Namespace Prefix:	ibio_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The effective ownership of the outstanding shares of the Company's common stock immediately after exercise of warrants - threshold percentage for which warrant holders may not exceed.

+ References

No definition available.

+ Details

Name:	ibio_OwnershipThresholdPercentage
Namespace Prefix:	ibio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The effective ownership of the outstanding shares of the Company's common stock, with written notice given by the holder to the Company, immediately after exercise of warrants - threshold percentage for which warrant holders may not exceed.

+ References

No definition available.

+ Details

Name:	ibio_OwnershipThresholdPercentageElectionOfHolder
Namespace Prefix:	ibio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of business days following the each calendar quarter within which placement agent fee is required to pay.

+ References

No definition available.

+ Details

Name:	ibio_PlacementAgentFeeQuarterlyPaymentDuePeriod
Namespace Prefix:	ibio_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Per share amount for each unit which includes 1 pre-funded warrant and 1 common share warrant.

+ References

No definition available.

+ Details

Name:	ibio_SaleOfStockPricePerUnitPreFundedWarrantsAndCommonShareWarrants
Namespace Prefix:	ibio_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Period during which the Company is obligated to pay placement agent fees related to cash exercises of warrants, measured from the closing of the related transaction, as specified in the underwriting agreement.

+ References

No definition available.

+ Details

Name:	ibio_UnderwritingArrangementWarrantExerciseRelatedFeeTerm
Namespace Prefix:	ibio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Underwriting fee paid to agent for the sale of stock, expressed as a percentage of gross proceeds received.

+ References

No definition available.

+ Details

Name:	ibio_UnderwritingDiscountFeePercentage
Namespace Prefix:	ibio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Minimum days of prior written notice needed to satisfy the holder's election to exercise warrants that give the holder, together with affiliates, a beneficial ownership in the Company's common stock of not more than 9.99%.

+ References

No definition available.

+ Details

Name:	ibio_WarrantExercisesOwnershipLimitationTermOfWrittenNotice
Namespace Prefix:	ibio_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Shares of stock issued as a result of the exercise of warrants.

+ References

No definition available.

+ Details

Name:	ibio_WarrantsExercisesInPeriodForCommonStock
Namespace Prefix:	ibio_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Pre-funded warrants issued as a result of the exercise of warrants.

+ References

No definition available.

+ Details

Name:	ibio_WarrantsExercisesInPeriodForPreFundedWarrants
Namespace Prefix:	ibio_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Name:	us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 340
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.A)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1

+ Details

Name:	us-gaap_DeferredOfferingCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-15

+ Details

Name:	us-gaap_PaymentsOfStockIssuanceCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash inflow associated with the amount received from holders exercising their stock warrants.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14

+ Details

Name:	us-gaap_ProceedsFromWarrantExercises
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedPerTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsidiarySaleOfStockLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

+ Details

Name:	us-gaap_WarrantsAndRightsOutstandingTerm
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesGAndSeriesHWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesGWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesHWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrants2025Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedSeriesGWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedSeriesHWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsidiarySaleOfStockAxis=ibio_LeerinkUnderwritingAgreement2025Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementOfFinancialPositionLocationBalanceAxis=us-gaap_AccruedLiabilitiesCurrent
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsAndSeriesGWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Stockholders' Equity - Leerink Underwriting (Details) - USD ($)		12 Months Ended
	Aug. 19, 2025	Jun. 30, 2026	Jun. 30, 2025
Stockholders' Equity
Underwriting fees		$ 5,860,000	$ 294,000
Proceeds from the exercise of warrants		33,400,000
Series G and Series H Warrants
Stockholders' Equity
Proceeds from the exercise of warrants		$ 25,000,000
Series G Warrants
Stockholders' Equity
Warrants exercised for common stock		14,160,000
Warrants exercised for pre-funded warrants		35,770,000
Series H Warrants
Stockholders' Equity
Number of shares which may be issued upon conversion of warrants		35,770,000
Warrants exercised for pre-funded warrants		4,250,000
2025 Pre-Funded Warrants
Stockholders' Equity
Warrants exercised for common stock		9,250,394
Proceeds from the exercise of warrants		$ 9,250
Pre-funded Series G Warrants
Stockholders' Equity
Number of shares which may be issued upon conversion of warrants		21,610,000
Warrants exercised for common stock		1,970,000
Proceeds from the exercise of warrants		$ 1,970
Pre-funded Series H Warrants
Stockholders' Equity
Number of shares which may be issued upon conversion of warrants		4,250,000
Proceeds from the exercise of warrants		$ 3,000,000
2025 Underwriting Agreement
Stockholders' Equity
Number of common stock shares issued	71,540,000
Warrant exercise, common stock ownership limitation	4.99%
Warrant exercise, common stock ownership limitation (at the election of the holder)	9.99%
Warrant holder's election, period of written notice	61 days
Ownership threshold percentage	4.99%
Gross proceeds from sale of equity	$ 50,000,000
Underwriting fees	3,600,000
Net proceeds from sale of equity	$ 46,400,000
Underwriting discount percentage	6.00%
All cash exercises of warrants, period	30 months
Placement agent fee, quarterly payment due period	5
Transaction fees		1,680,000
2025 Underwriting Agreement \| Maximum
Stockholders' Equity
Warrant exercise, common stock ownership limitation	19.99%
Ownership threshold percentage	19.99%
2025 Underwriting Agreement \| Location, Statement of Financial Position, Balance [Axis]: us-gaap:AccruedLiabilitiesCurrent
Stockholders' Equity
Transaction fees		1,173,000
2025 Underwriting Agreement \| Series G and Series H Warrants
Stockholders' Equity
Warrants, exercise price	$ 0.7
Additional gross proceeds available upon exercise of warrants		22,100,000
Proceeds from the exercise of warrants		$ 26,300,000
2025 Underwriting Agreement \| Series G Warrants
Stockholders' Equity
Number of shares which may be issued upon conversion of warrants	35,770,000
Warrants, exercisable term	5 years
2025 Underwriting Agreement \| Series H Warrants
Stockholders' Equity
Number of shares which may be issued upon conversion of warrants	35,770,000
Warrants, exercisable term	4 years
2025 Underwriting Agreement \| 2025 Pre-Funded Warrants
Stockholders' Equity
Warrants, exercise price	$ 0.001
2025 Underwriting Agreement \| Pre-funded Series G Warrants
Stockholders' Equity
Number of shares which may be issued upon conversion of warrants	35,770,000
Warrants, exercise price	$ 0.001
2025 Underwriting Agreement \| Pre-funded Series H Warrants
Stockholders' Equity
Number of shares which may be issued upon conversion of warrants	35,770,000
Warrants, exercise price	$ 0.001
2025 Underwriting Agreement \| Pre Funded Warrants and Series G Warrants
Stockholders' Equity
Combined purchase price of each Pre-Funded Warrant and the accompanying Common Warrants	$ 0.699